<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02796118</url>
  </required_header>
  <id_info>
    <org_study_id>15L-CL-003</org_study_id>
    <nct_id>NCT02796118</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Pharmacokinetics of ASP2151 in Healthy Non-elderly and Elderly Subjects</brief_title>
  <official_title>ASP2151 Phase 1 Study - Multiple Oral Dosing Study in Healthy Non-elderly Male and Elderly Male Japanese Subjects-</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and the pharmacokinetics of ASP2151
      after multiple oral dosing of ASP2151 in healthy non-elderly male and elderly male Japanese
      subjects, and to compare the pharmacokinetics of ASP2151 in healthy non-elderly male and
      elderly male Japanese subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of ASP2151 in plasma: Cmax</measure>
    <time_frame>Up to Day 9</time_frame>
    <description>Cmax: Maximum concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of ASP2151 in plasma: tmax</measure>
    <time_frame>Up to Day 9</time_frame>
    <description>tmax: The time after dosing when Cmax occurs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of ASP2151 in plasma: t1/2</measure>
    <time_frame>Up to Day 9</time_frame>
    <description>t1/2: Apparent terminal elimination half-life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of ASP2151 in plasma: C24</measure>
    <time_frame>Up to Day 9</time_frame>
    <description>C24: Concentration at 24hours after dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of ASP2151 in plasma: AUC24</measure>
    <time_frame>Up to Day 9</time_frame>
    <description>AUC24: Area under the concentration-time curve from the time of dosing to 24hours after dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of ASP2151 in plasma: AUCinf</measure>
    <time_frame>Up to Day 9</time_frame>
    <description>AUCinf: Area under the concentration-time curve from the time of dosing extrapolated to time infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of ASP2151 in plasma: CL/F</measure>
    <time_frame>Up to Day 9</time_frame>
    <description>CL/F: Apparent total systemic clearance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of ASP2151 in urine: Ae</measure>
    <time_frame>Up to Day 9</time_frame>
    <description>Ae: Amount excreted in urine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of ASP2151 in urine: Cumulative Ae</measure>
    <time_frame>Up to Day 9</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of ASP2151 in urine: Ae%</measure>
    <time_frame>Up to Day 9</time_frame>
    <description>Ae%: Percent of ASP2151 amount excreted in urine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of ASP2151 in urine: Cumulative Ae%</measure>
    <time_frame>Up to Day 9</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of ASP2151 in urine: CLR</measure>
    <time_frame>Up to Day 9</time_frame>
    <description>CLR: Renal clearance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by laboratory test: Hematology</measure>
    <time_frame>Up to Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by laboratory test: blood biochemistry</measure>
    <time_frame>Up to Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by laboratory test: urinalysis</measure>
    <time_frame>Up to Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by Vital sign measurement: axillary body temperature</measure>
    <time_frame>Up to Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by vital sign measurement: supine blood pressure</measure>
    <time_frame>Up to Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by vital sign measurement: supine pulse rate</measure>
    <time_frame>Up to Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by Standard 12-lead electrocardiogram</measure>
    <time_frame>Up to Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by Standard 12-lead electrocardiogram for QT assessment</measure>
    <time_frame>Up to Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by ophthalmological examination</measure>
    <time_frame>Up to Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by incidence of adverse events</measure>
    <time_frame>Up to Day 14</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>ASP2151 Low dose in non-elderly subjects group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive ASP2151 daily on Days 1 to 7.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASP2151 High dose in non-elderly subjects group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive ASP2151 daily on Days 1 to 7.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASP2151 Low dose in elderly subjects group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive ASP2151 daily on Days 1 to 7.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASP2151 High dose in elderly subjects group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive ASP2151 daily on Days 1 to 7.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo in non-elderly subjects group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive matching placebo daily on Days 1 to 7.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo in elderly subjects group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive matching placebo daily on Days 1 to 7.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP2151</intervention_name>
    <description>Oral</description>
    <arm_group_label>ASP2151 Low dose in non-elderly subjects group</arm_group_label>
    <arm_group_label>ASP2151 High dose in elderly subjects group</arm_group_label>
    <arm_group_label>ASP2151 Low dose in elderly subjects group</arm_group_label>
    <arm_group_label>ASP2151 High dose in non-elderly subjects group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral</description>
    <arm_group_label>Placebo in elderly subjects group</arm_group_label>
    <arm_group_label>Placebo in non-elderly subjects group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body weight: ≥50.0 kg and &lt;85.0 kg

          -  Body mass index (BMI): ≥17.6 and &lt;26.4 kg/m2

        Exclusion Criteria:

          -  Subjects with a complication of any diseases

          -  Subjects with a history of hepatic disease

          -  Subjects with a history of heart disease

          -  Subjects with a history of respiratory disease

          -  Subjects with a history of alimentary disease

          -  Subjects with a history of renal disease

          -  Subjects with a history of cerebrovascular disorder

          -  Subjects with a history of malignant tumor

          -  Subjects with a history of drug allergies or allergies disorders excluding pollinosis

          -  Subjects with a history of drug dependency or alcohol dependence syndrome

          -  Subjects who developed genital herpes or herpes zoster within 90 days before the
             initial dosing

          -  Subjects who do not meet any of the criteria for laboratory tests

          -  Subjects who received medications within 14 days before the initial dosing.

          -  Subjects who received any investigational drugs in other clinical trials or
             post-marketing studies within 120 days before screening or the initial dosing

          -  Excessive alcohol drinking or smoking habit

          -  Subjects who previously received administration of ASP2151 (including placebo)

          -  Abnormalities detected on an ophthalmological examination

          -  Subjects who deviate from the normal range of standard 12-lead ECG at screening
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site JP00001</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2016</study_first_submitted>
  <study_first_submitted_qc>June 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2016</study_first_posted>
  <last_update_submitted>August 25, 2016</last_update_submitted>
  <last_update_submitted_qc>August 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Healthy non-elderly and elderly subjects</keyword>
  <keyword>ASP2151</keyword>
  <keyword>Safety</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

